Change of Tregs cells percentage, interferon-γ, interleukin-4 and CD25 level in sepsis patients of intensive care unit

doi:10.3969/j.issn.1004-583X.2016.01.016

Abstract

Abstract: Objective To observe the change of CD4⁺CD25⁺regulatory T cells(Tregs) in early-stage sepsis patients of intensive care unit(ICU).Methods The subjects were 74 early-stage sepsis patients in ICU of Tianjin People's Hospital from June 2012 to December 2013,30 patients with systemic inflammatory response syndrome (SIRS) and 44 healthy controls. The percentage of Tregs cells in the blood, the level of plasma interferon-γ(IFN-γ),interleukin-4(IL-4) and soluble CD25 of the early-stage sepsis patients were tested.Results Compared with the control group, the level of plasma IFN-γ and IL-4 in the early-stage sepsis patients increased significantly(P<0.01). The value of IFN-γ/IL-4 was significantly higher in patients with sepsis and SIRS(P<0.01).There were no difference about the indicators between SIRS patients and early-stage sepsis patients (P>0.05). The percentage of Tregs in early-stage sepsis patients was significantly higher than that of SIRS and health control cases(P<0.01). Using the percentage of Tregs could distinguish early-stage sepsis and SRIS. The plasma soluble CD25 levels in patients with early-stage sepsis also improved significantly, and the level was positively correlated with the percentage of Tregs(r=0.391,P=0.004).Conclusion The results suggest that Tregs can be used as an index of early diagnosis of sepsis, and using the percentage of Tregs could distinguish early-stage sepsis and SRIS. The ratio can be used for evaluating immune status in patients and help doctors formulate the best immune adjustment therapy.

Key words: systemic inflammatory response syndrome, sepsis, intensive care

CLC Number:

R631

Dong Hong, Zhang Huizhi,Qian Qinjuan. Change of Tregs cells percentage, interferon-γ, interleukin-4 and CD25 level in sepsis patients of intensive care unit[J]. Clinical Focus, 2016, 31(1): 63-67.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.01.016

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I1/63

References

[1] 汪勤,赵春辉,蔡琴,等. 脓毒症患者外周血微小RNA-155和调节性T细胞表达的关系[J]. 中华危重病急救医学, 2014, 26(3):179-183.
[2] 吕红, 潘宗琴, 胡世芸, 等. CD4＋CD25＋调节性T细胞与不同HBV感染状态的研究进展[J]. 世界华人消化杂志, 2014, 22(10):1373-1377.
[3] Hotchkiss RS, Coopersmith CM, McDunn JE, et al. The sepsis seesaw: tilting toward immunosuppression[J]. Nat Med, 2009, 15(5):496-497.
[4] 李俊艳, 董晨明, 宋瑞霞. 胸腺肽α1在脓毒症的应用及研究新进展[J]. 临床荟萃, 2015, 30(4):468-471.
[5] Frazier WJ, Hall MW. Immunoparalysis and adverse outcomes from critical illness[J]. Pediatr Clin North Am, 2008,55(3):647-668.
[6] 陆程翔, 孙德军, 邱婷. 乳酸清除率对感染性创面致严重脓毒症及脓毒性休克患者治疗效果及预后的评估作用[J]. 临床荟萃, 2015,30(10):1152-1156.
[7] 袁远宏,肖政辉,张慧,等. 连续血液净化对严重脓毒症患儿T细胞亚群的影响[J]. 中国当代儿科杂志. 2014, 16(2):194-197.
[8] 牛开亚, 杨帆, 杨晓燕, 等. 尿肝型脂肪酸结合蛋白和尿中性粒细胞明胶酶相关脂质运载蛋白用于诊断严重脓毒症患者急性肾损伤[J]. 临床荟萃, 2015, 30(5):536-539.
[9] 毕德飞, 赵雷, 钱风华, 等.尿N-乙酰-β-D-氨基葡萄糖苷酶在脓毒症并发早期肾功能损害中的诊断价值[J]. 临床荟萃, 2014, 29(3)315-317.
[10] Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure[J]. JAMA, 2011, 306(23):2594-2605.
[11] 刘洋, 胡大海, 董茂龙, 等. 负压创面治疗对烧伤创面脓毒症小鼠死亡率的影响[J]. 解放军医药杂志, 2013, 25(12):16-19.
[12] Aziz M, Yang WL, Matsuo S, et al.Upregulation of GRAIL Is Associated with Impaired CD4 T Cell Proliferation in Sepsis[J].J Immunol, 2014, 192(5):2305-2314.
[13] 刘博, 李绍光, 孙天胜. Treg细胞与Th17细胞的研究现状及临床意义[J]. 解放军医药杂志, 2013,25(4): 89-93.
[14] Venet F, Chung CS, Monneret G, et al. Regulatory T cell populations in sepsis and trauma[J].J Leukoc Biol,2008, 83(3):523-535.
[15] 杨秀芬, 李栋梁, 周庆明. 脓毒症致肠功能衰竭研究进展[J]. 河北医科大学学报, 2014, 35(11):1357-1360.
[16] Gouel-Chéron A, Allaouchiche B, Floccard B, et al. Early daily mHLA-DR monitoring predicts forthcoming sepsis in severe trauma patients[J]. Intensive Care Med, 2015, 41(12): 2229-2230.
[17] Monneret G,Debard AL,Venet F,et al. Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis[J].Crit Care Med, 2003, 31(7):2068-2071.
[18] Cook DN,Hollingsworth JW Jr,Schwartz DA. Toll-like receptors and the genetics of innate immunity[J].Curr Opin Allergy Clin Immunol, 2003,3(6):523-529.
[19] Amancha PK, Hong JJ, Rogers K, et al.In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4⁺ and CD8⁺ T cell responses but has limited clinical benefit[J].J Immunol, 2013, 191(12):6060-6070.
[20] Lucas CL, Kuehn HS, Zhao F, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cellsenescence and human immunodeficiency[J].Nat Immunol, 2014, 15(1):88-97.